AI Article Synopsis
- This study examined how different doses of sacubitril/valsartan affect hospitalization and mortality in patients with heart failure and reduced ejection fraction (HFrEF).
- It involved a multicenter analysis of 721 patients, narrowing down to 652 after matching based on similar characteristics to compare three dosage groups (24/26 mg, 49/51 mg, and 97/103 mg).
- Results showed that higher doses (49/51 mg and 97/103 mg) significantly reduced hospitalization and mortality rates compared to the lowest dose (24/26 mg).
Article Abstract
Background: Limited evidence is available regarding low (24/26 mg) and middle (49/51 mg) doses of sacubitril/valsartan.
Objectives: The purpose of this study was to investigate the effect of sacubitril/valsartan dose on heart failure (HF) hospitalization and mortality in patients with HF with reduced ejection fraction (HFrEF).
Methods: A retrospective multicenter cohort study compared 3 doses of sacubitril/valsartan in patients with HFrEF. The coprimary outcomes were all-cause mortality and rehospitalization for HF. Propensity matching analysis was performed.
Results: Of 721 eligible patients, propensity matching created a cohort with an effective sample size of 652 (24/26-mg group [n = 326], 49/51-mg group [n = 147], 97/103-mg group [n = 179]). The HF hospitalization rates were 29.14% in the 24/26-mg group, 19.51% in the 49/51-mg group, and 16.10% in the 97/103-mg group (24/26 vs 49/51 mg: HR = 1.56, 95% CI = 1.04-2.34; 24/26 vs 97/103 mg: HR = 1.79, 95% CI = 1.18-2.73; 49/51 vs 97/103 mg: HR = 1.15, 95% CI = 0.70-1.89). All-cause mortality rates were 29.63% in the 24/26-mg group, 17.58% in the 49/51-mg group, and 9.27% in the 97/103-mg group (24/26 vs 49/51 mg: HR = 1.67, 95% CI = 1.07-2.59; 24/26 vs 97/103 mg: HR = 2.56, 95% CI = 1.54-4.24; 49/51 vs 97/103 mg: HR = 1.54, 95% CI = 0.84-2.82).
Conclusion And Relevance: Sacubitril/valsartan 97/103- or 49/51-mg dose is associated with a lower mortality or hospitalization rate for HF in patients receiving sacubitril/valsartan compared with the 24/26-mg dose group.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381284 | PMC |
| http://dx.doi.org/10.1177/1060028020983522 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of angiotensin receptor neprilysin inhibitor on physical activity in patients with heart failure with reduced ejection fraction, monitored by implantable electronic device home monitoring.
J Cardiovasc Med (Hagerstown)
March 2024
Department of Cardiology.
Aims: Angiotensin receptor neprilysin inhibitor (ARNI) therapy is a cornerstone in the treatment of heart failure with reduced ejection fraction (HFrEF), with significant improvement in mortality as well as morbidity and quality of life. However, maximal ARNI doses often result in hypotension. Recent studies with 'real world' experience suggest that lower doses of ARNI are as effective as higher doses.
View Article and Find Full Text PDFUse of sacubitril/valsartan early after CABG.
Open Heart
January 2024
Scientific Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan
Background: Heart failure (HF) remains a major public health problem with a high mortality and morbidity worldwide. Currently, there is no optimal revascularisation strategy for patients with ischaemic cardiomyopathy despite suggestions that coronary artery bypass graft (CABG) may be superior to medical therapy in improving survival. However, CABG may be associated with substantial risk in HF subjects.
View Article and Find Full Text PDFUp-Titration of Sacubitril/Valsartan Among Patients With Heart Failure and Preserved Ejection Fraction.
J Cardiovasc Pharmacol Ther
January 2023
Department of Cardiology, Kindai University Faculty of Medicine, Osakasayama, Japan.
Aims: In recent large trials, sacubitril/valsartan demonstrated favorable effects in patients with HF. However, many patients do not achieve the target dose of treatment. This study investigated the factors linked to up-titration of sacubitril/valsartan in patients with heart failure and preserved ejection fraction (HFpEF).
View Article and Find Full Text PDFArticle Synopsis
- This study examined how different doses of sacubitril/valsartan affect hospitalization and mortality in patients with heart failure and reduced ejection fraction (HFrEF).
- It involved a multicenter analysis of 721 patients, narrowing down to 652 after matching based on similar characteristics to compare three dosage groups (24/26 mg, 49/51 mg, and 97/103 mg).
- Results showed that higher doses (49/51 mg and 97/103 mg) significantly reduced hospitalization and mortality rates compared to the lowest dose (24/26 mg).
Novel doses of sacubitril/valsartan in patients unable to tolerate traditional therapy: Effects on N-terminal pro B-type natriuretic peptide levels.
Clin Cardiol
January 2021
Division of Cardiology, Scripps Prebys Cardiovascular Institute, Scripps Clinic, La Jolla, California, USA.
Background: Widespread use of angiotensin receptor blocker and neprilysin inhibitor (ARNI) remains low, and many patients are unable to tolerate the medication due to hypotension at the currently recommended starting dose.
Hypothesis: The aim of this study is to assess if lower than standard doses of ARNI, sacubitril/valsartan (S/V), significantly reduces NT-proBNP and leads to any change in diuretic dose, serum potassium, or creatinine.
Methods: In a retrospective study of 278 patients who were started on a low dose S/V at a single medical center, 45 patients were selected for the study cohort.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!